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ABSTRACT
Methyl-CpG-binding protein 2 (MeCP2) is a
chromatin-binding protein that mediates transcrip-
tional regulation, and is highly abundant in brain.
The nature of its binding to reconstituted templates
has been well characterized in vitro. However, its
interactions with native chromatin are less under-
stood. Here we show that MeCP2 displays a
distinct distribution within fractionated chromatin
from various tissues and cell types. Artificially
induced global changes in DNA methylation by
3-aminobenzamide or 5-aza-20-deoxycytidine, do
not significantly affect the distribution or amount
of MeCP2 in HeLa S3 or 3T3 cells. Most MeCP2 in
brain is chromatin-bound and localized within highly
nuclease-accessible regions. We also show that,
while in most tissues and cell lines, MeCP2 forms
stable complexes with nucleosome, in brain, a
fraction of it is loosely bound to chromatin, likely
to nucleosome-depleted regions. Finally, we
provide evidence for novel associations of MeCP2
with mononucleosomes containing histone H2A.X,
H3K9me2 and H3K27me3 in different chromatin frac-
tions from brain cortex and in vitro. We postulate
that the functional compartmentalization and
tissue-specific distribution of MeCP2 within differ-
ent chromatin types may be directed by its associ-
ation with nucleosomes containing specific histone
variants, and post-translational modifications.
INTRODUCTION
The precise and dynamic modulation of chromatin struc-
ture is essential for context-speciﬁc transcriptional, or
replication-dependent processes. Chromatin alterations
resulting from the disruption of such processes are trace-
able and provide potentially useful disease biomarkers (1).
Mutations in the chromatin-binding protein, methyl–
CpG-binding protein 2 (MeCP2), have been linked to
the neurodevelopmental disorder Rett syndrome (RTT)
and other neurological abnormalities (2,3).
MeCP2 is a member of the methyl–CpG-binding
domain (MBD) family of proteins (4). MeCP2 can bind
symmetrically methylated 50-CpG dinucleotides that are
located proximal to at least four A/T nucleotides within
the surrounding 11bp (5). This binding is dependent on
the recognition of the hydrated methylated CpG by the
wedge-shaped MBD (6,7).
Most work characterizing MeCP2 interactions with
chromatin has been done with reconstituted templates.
Under such conditions, MeCP2 has been shown to
bind both methylated and unmethylated templates, with
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competitor DNA (8,9). Under non-physiological ionic
conditions, MeCP2 was demonstrated to condense
unmethylated chromatin templates (10). Upon binding
to nucleosomes, MeCP2 forms chromatosome-like struc-
tures and may even facilitate inter-nucleosomal ﬁber inter-
actions in vitro (11). Early studies indicated that MeCP2 is
able to compete with histone H1 for binding linker DNA,
and is able to displace  40% of H1 (12). In vitro recon-
stitution of nucleosomes containing preferential binding
sites for MeCP2 indicated that it preferred binding
within 10bp of the dyad axis (8,11). By contrast, the inter-
actions of MeCP2 with native chromatin are less exten-
sively characterized.
Much of the early work done on MeCP2 characterized
it as a transcriptional repressor due to its association with
histone deacetylases (HDACs, HDAC 1 and 2) and
SIN3A (4,13). As well, MeCP2 was shown to associate
with SUV39H1, the histone methyltransferase responsible
for methylating lysine 9 of histone H3 (14), an activity
also linked to the DNA methyltransferase, DNMT3A
(15). Furthermore, involvement of MeCP2 in long-range
silencing was shown through its ability to form chromatin
loops containing the gene Dlx5 (16). Nevertheless, the per-
spective began to change with recent publications
demonstrating that the majority of MeCP2-bound pro-
moters were positively regulated (17,18). MeCP2 has
been shown to localize to a broad range of chromatin
types, supporting observations of a potential plurality to
MeCP2 function (8). However, besides the requirement
for sequence-speciﬁcity and DNA methylation, very little
is known about the histone determinants [histone variants
and post-translational modiﬁcations (PTMs)] associated
with this multifaceted functionality.
In this paper, we look at the chromatin distribution of
MeCP2 in several tissues, and characterize the histone
composition variability of nucleosomes with which
MeCP2 is associated in the brain.
MATERIALS AND METHODS
Biotin-conjugated peptides pull-down and immunoblotting
Biotinylated histone peptides were purchased from
Anaspec (Anaspec, Fremont, CA). The following
peptides were used: 1. Histone H3 (1–21)—GGK(Biotin),
H3K9/14(Ac); 2. Histone H3 (1–21)—GGK (Biotin),
H3K4(Me2); 3. Histone H3 (1–21)—GGK(Biotin),
H3K4(Me3); 4 [Lys(Me3)
9]—Histone H3 (1–21)—
GGK(Biotin), H3K9(Me3); 5. [Lys (Me3)
27]—Histone H3
(21–44)—GK(Biotin), H3K27(Me3). Each peptide was
re-suspended in TGD (20mM Tris pH 8.0, 1mM EDTA,
0.1% Triton X-100) at a concentration of 1mg/ml, ﬂash
frozen and stored at  80 C until use. For each pull-down
experiment, 5mg of biotinylated histone H3 tail peptides
bound to streptavidin beads [Dynabeads M-280
Streptavidin, (Invitrogen, Carsbad, CA)] were incubated
with 0.5mg wild-type MeCP2 (previously dialyzed against
TGD), in the presence of 5mg of puriﬁed BSA, for 2h at
4 C with rotation. After three TGD washes to reduce
non-speciﬁc binding, MeCP2-bound peptides were
acid-eluted (100mM glycine pH 2.8) from the beads. The
eluates and supernatant representing 40% total input were
subjected to SDS–PAGE, transferred to nitrocellulose
membranes, probed for the presence of MeCP2 using an
N-terminal speciﬁc antiMeCP2 antibody [Abcam
(Cambridge, UK), ab2828], and visualized with ECL (GE
Health Care Life Sciences, Piscataway, NJ) according to
the manufacturer’s protocol.
Cytoplasmic and nuclear fractionation
HeLa cell cytoplasmic and nuclear fractions were
prepared using an Active Motif kit (Active motif,
Carlsbad, CA). Western blots for analysis of the MeCP2
content were normalized based on the volumes of each
fraction that corresponded to the same amount of cells.
Preparation of nuclei and chromatin fractionation
Nuclei and chromatin from different cell lines and tissues
were prepared as described in the Supplementary Data
section.
Salt extraction of MeCP2 from rat brain and liver nuclei
Nuclei were prepared as described above, with inclusion of
20mM EDTA in all buffers in the case of liver. Salt
extracts were prepared by extracting equal aliquots of
nuclei with 10mM Tris pH 7.5 supplemented with concen-
trations of NaCl ranging from 0.10 to 0.50 M, in 0.05 M
steps as, previously described (19), and in the case of liver
nuclei, 10mM EDTA. Preparations were vortexed vigor-
ously and left on ice to incubate for 20min, followed by
centrifugation at 16000g. All extractions were carried out
in the presence of Roche Complete Protease Cocktail
Inhibitor.
Sucrose gradient fractionation
S1 and SE supernatants were run on 5–20% sucrose gra-
dients in 25mM NaCl, 10mM Tris pH 7.5 and 5mM
EDTA buffer for 21h at 96000g and 4 C, and collected
thereafter in 0.5ml aliquots.
Gel electrophoresis
SDS–(15%) PAGE (20), acetic acid-urea (AU)- PAGE
(21), acetic acid-urea-triton X-100 (AUT)—(10%)
PAGE (22), Native– (4%) PAGE (23) and 0.7% agarose
gels were performed as described earlier (24,25).
Western blotting
Western analysis was carried out as in (26). The antibodies
and the dilutions used were as follows: MeCP2 [Sigma
(St. Louis, MO), M9317] 1:2500, H3K27me3 [Millipore
(Billerica MA, 07-449] 1:5000, H3K9me2 [Upstate/
Millipore (Billerica, MA), 07-212] 1:2000, H2A.X [abm
(Vancouver, BC), Y021260] 1:3333, H2A.Xg [Millipore
(Billerica, MA), 07-164] 1:1000, H2A.Z [Abcam
(Cambridge, UK), ab4174] 1:1000, H2A.Z acetylated
(generous gift from Dr. Crane-Robinson) 1:1000, H4
(made in-house) 1:10000, H4 pan acetylated [Upstate/
Millipore (Billerica, MA), 06-866] 1:4000, H3K4me3
[Millipore (Billerica, MA), 04-745) 1:5000.
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The relative amount of 50-methylcytosine was analyzed
by HPLC using a strong cation exchange (SCX) column
(27) and the base preparation conditions described in
(28). In brief, digestion buffer from a 10  stock
(200mM acetic acid, 200mM glycine, 50mM MgCl2,
5mM ZnCl2 and 2mM CaCl2, adjusted to pH 5.3 with
NaOH), was added to 10–20mg of DNA, which had been
puriﬁed with a Qiagen (Qiagen, Germantown, MD) PCR
kit. This was then treated with 1:50 of nuclease mix
[2.5U/ml nuclease P1 (Sigma-Aldrich, Saint Louis, MO)
and 500U/ml DNase I in 50% glycerol]. The mixture was
incubated overnight at 37 C, and followed by an addition-
al overnight incubation with one unit of Antarctic phos-
phatase (New England Biolabs) at 37 C. Immediately
prior to injection, the sample was diluted 2  with
12mM HCl, and resolved on a Luna SCX
(Phenomenex, Torrance, CA) column at a ﬂow rate of
1ml/min, with isocratic gradient of 40mM acetic acid
and 15% acetonitrile, pH 4.8.
Real-time quantitative RT–PCR
RT–PCR experiments were performed as described else-
where (29). The comparative Ct (2
 Ct) method was used
to quantify the relative fold changes in MECP2 expression
levels between different treatment conditions or tissues
(30–32). A serial dilution validation assay was performed
to assess the appropriateness of the target and reference
gene primers for RT–PCR. For all primer sets, when
plotting the log cDNA concentration dilution to the Ct
value, the slope of the line was <0.1, and efﬁciencies of the
primer sets were >99%.
Two sets of primers were used to amplify MECP2:1 ;
[forward: 50-AGCCATCAGCCCACCACT, reverse: 50-C
GCAATCAACTCCACTTTAGA ( 281-bp amplicon)]
(HeLa cells), 2: [forward 50-GCCTCTGCTTCTCCCAA
AC and reverse 50-CCACCTCCCTCACCCTTAC
(485-bp amplicon)] (rat tissues). These primers were
designed to amplify both MECP2 isoforms. After it was
found that GAPDH (glyceraldehyde-3-phosphate de-
hydrogenase) exhibited a signiﬁcant extent of variation
across different tissues, rat GC-rich promoter-binding
protein 1 gene (GPBP1) was instead used as a reference
to normalize the target gene (MECP2) and to account for
any variations that may be present in reference gene levels
between the different tissues (33). The primers used for
[GPBP1 were: [forward 50-CTTAGTCCCCAAACCTGC
TG and reverse 50-TGAGAAATCACCGAGGCATT
(462-bp amplicon)].
The Invitrogen Platinum SYBR Green qPCR
SuperMix-UDG with Rox was used in the experiments
described. For each reaction, 7.5ml of the SYBR mix
was added to 0.5ml1 0 mM primers, 2ml 1/20 diluted
cDNA and 5ml of RNase- and DNase-free dH2O.
For each cDNA dilution prepared, the reaction was run
in quadruplicate per primer set. A non-template control
was run to test the primers independently as well.
The RT–PCR was done using an Agilent Technologies
Stratagene Mx3005P instrument and MxPro – Mx3005P
v4.10 Build 389, Schema 85 software (Stratagene).
The run parameters were as follows. Segment 1 (one
cycle): denaturation at 94 C for 9min; Segment 2 (40
cycles): denaturation at 95 C for 15s, annealing at 62 C
for 30s, and extension at 72 C for 45s; Segment 3 (one
cycle—for dissociation proﬁle): 95 C for 1min, 55 C for
30s, 95 C for 30s. Data analysis was done using the
2
 Ct method, with the untreated (native) HeLa S3
culture used as the comparator for 3-ABA -treated
cultures, in order to determine the relative fold changes
in transcript levels. In the tissue analysis, a mixed cDNA
comparator was prepared in which 2ml of each 1/20
cDNA dilution for every tissue was combined together
and run as a separate sample (31). Every tissue cDNA 1/
20 dilution was run in triplicate, as were non-template
(primer) controls.
Native coimmunoprecipitation of MeCP2-bound
mononucleosomes
Sheep cortex tissues were used to produce the
mononucleosome-containing S1 and SE chromatin frac-
tions following the procedure described above. To
ensure that the antibody binding capacity was saturated,
an excess starting material was used for both the S1 and
SE coimmunoprecipitations. In paired MeCP2 antibody
and normal rabbit IgG pull-down reactions, 350mgo fS 1
chromatin was added to 50mM NaCl, 20mM Tris pH 7.5
to a ﬁnal volume of 1.0ml. In similarly paired pull-down
reactions, 250mg of SE chromatin was added to 100mM
NaCl, 20mM Tris pH 7.5 and brought to a ﬁnal concen-
tration of 50mM NaCl in a total volume of 1.0ml. An
amount of 5.0mg of salmon sperm DNA (Invitrogen,
Carlsbad, CA) was added to block any non-speciﬁc inter-
actions. A 5min pre-clearing of the sample with 15mlo fa
50:50 slurry of protein A/G agarose beads (Pierce/Thermo
Scientiﬁc, Rockford, IL) at 4 C with tumbling was initially
done to reduce any non-speciﬁc binding to the beads
(34). Following a brief centrifugation to remove the
beads (700g, 3min, 4 C), 12ml of each pre-cleared input
supernatant was kept aside for later analysis. To the
MeCP2 pull-downs, 15ml of 0.6mg/ml primary
anti-MeCP2 antibody (Sigma, St. Louis, MO) was added
to the remaining supernatant, while 9ml of a 1mg/ml
normal rabbit IgG (Sigma, St. Louis, MO) was added to
the non-speciﬁc pull-down control. Reactions were
tumbled at 4 C overnight. An amount of 100ml of A/G
bead slurry (Pierce/Thermo Scientiﬁc, Rockford, IL) were
added to all reactions and tumbled at 4 C for 2h. The
suspension was brieﬂy centrifuged as above and the
unbound supernatants were kept aside. The pull-down
beads were subsequently washed by inversion in 1.0ml
each of 5mM NaCl, 50mM NaCl and 100mM NaCl, in
20mM Tris (pH 7.5) buffers. The recovered bound beads
were then resuspended in 20ml2   SDS sample buffer and
heated at 100 C for 3min and analyzed by SDS–PAGE
and western blotting.
Immunoﬂuorescence
Wax was removed from slides by heating slides at 60 C,
and parafﬁn removal was achieved by three washes in a
xylene bath followed by a reverse ethanol series from
2886 Nucleic Acids Research, 2012,Vol.40, No. 7100% ethanol through to water. Slides were then washed
with TBS-Tween 20 (0.05%)(TBS-T). For antigen re-
trieval, a microwave antigen retrieval was performed in
100mM trisodium citrate with 0.05% Tween 20 pH 6.0.
Following antigen retrieval, slides were blocked with 4%
BSA in TBS-T for 1h followed by incubation for 2h at
room temperature with primary antibody [Sigma (St.
Louis, MO) M9317] at a dilution of 1:1000. The slides
were then washed 3  in TBS-T and then incubated with
an Alexa 488-conjugated secondary antibody. After
washing, the slide was then mounted in polyvinyl
alcohol containing 1mg/ml DAPI.
Electron microscopy
Male rat brain cortical tissue was ﬁxed overnight in 3%
glutaraldehyde/3% formaldehyde in 0.1M cacodylate
buffer and further sliced into small pieces for Epon, pro-
cessing/embedding. The samples were post-ﬁxed in 1%
osmium tetroxide, en bloc stained in 5% uranyl acetate
in 50% ethanol, and completely dehydrated through a
graded ethanol series and inﬁltrated with Epon through
graded steps with propylene oxide. Individual brain pieces
were placed into individual gelatin capsules containing
new epon allowed to polymerize at 60 C for 48h.
Ultrathin sections were cut on a Reichert Ultracut E
with a diamond knife and placed onto 100 mesh nickel
grids containing a carbon-coated formvar ﬁlm. Sections
were treated with rabbit MeCP2 antibody [Sigma (St.
Louis, MO), M9317] and probed with 12nm colloidal
Gold-AfﬁnitiPure Goat anti-rabbit IgG (H+L), (Jackson
ImmunoResearch Inc, West Grove, PA). The sections
were pre-treated with saturated sodium metaperiodate in
water for 1h, blocked for 10min with PBS-ovalbumin
(1%), labeled with primary diluted (1:100 to 1:400) in
PBS-ovalbumin for 1h, washed with PBS-ovalbumin,
labeled with secondary diluted 1:100 in PBS-ovalbumin
for 1h, washed in PBS-ovalbumin and distilled water,
and stained in 5% uranyl acetate in 50% ethanol and
5% lead citrate. The sections were viewed in a Hitachi
H7000 TEM and images captured with an AMT
2k 2k CCD camera.
RESULTS
MeCP2 chromatin distribution does not depend on the
extent of global DNA methylation in cultured cells
Using a chromatin fractionation procedure (35,36)
(Supplementary Figure S1A), we have previously shown
that the majority of MeCP2 cofractionates with the highly
nuclease-accessible S1 chromatin fraction from HeLa
S3 cells (8). As shown in Supplementary Figure S1B,
most of the MeCP2 in this cell-type is of nuclear origin,
as only a very small fraction is associated with the
cytoplasm. Despite the simplicity of the chromatin frac-
tionation protocol we (26,29), and others (37), have
previously shown that the S1 corresponds to euchromatic
regions, and to chromatin regions at the periphery of
heterochromatin domains that are very accessible to
nucleases. The SE consists mainly of facultative
heterochromatin, and the pellet (P) fraction consists of
constitutive heterochromatin and regions of chromatin
associated with large multimeric (transcriptional and
DNA-repair) protein complexes (26,35,38). Such distribu-
tion is consistent with the histone variants and PTMs
observed here (see Supplementary Figure S1A, right
panel).
To ensure that the unusual MeCP2 distribution is not
an artifact of the buffers used during nuclei isolation and
further chromatin digestion, the chromatin preparation
and digestion were carried out using three different
methods (19,39,40) that utilize different buffers for the
micrococcal nuclease digestion (see Supplementary
Figure S1C). As shown, a very similar distribution of
MeCP2 is observed in all instances.
Early work, and our own in vitro analyses of MeCP2
binding to DNA and nucleosomes, has shown that the
protein binds preferentially to methylated DNA templates
(8,41). However, based on other in vitro studies (10), it has
been argued that MeCP2 may bind to chromatin in a dual
way that is dependent and independent of the methylated
state of DNA (42). Such conclusions need to be taken
cautiously as MeCP2, in addition to containing a methyl
DNA-binding domain (MBD), is a very basic protein
(pI=9.9), and under low ionic buffer conditions it may
bind to DNA in a non-speciﬁc way, whether
nucleosomally organized or not. In attempt to address
this issue in an in vivo setting, we used different
approaches to alter the level of genomic DNA methyla-
tion. To this end, HeLa and 3T3 mouse cell cultures were
treated with 3-aminobenzamide (3-ABA), and
5-aza-20-deoxycytidine, which alter the extent of DNA
methylation (Figure 1A). Importantly, none of these treat-
ments signiﬁcantly affected the proportion of chromatin in
the S1, SE, and P fractions, which remained at around
11±2% (S1); 30±3% (SE) and 59±5% (P) in HeLa
cells treated with +/  3-ABA and +/ 
5-aza-20-deoxycytidine. In the case of the 3T3 cells the
proportions were 11±1% (S1); 34±1% (SE) and
55±1% (P) for the cells treated with +/ 
5-aza-20-deoxycytidine and 10±1% (SI); 36±1% (SE)
and 54±1% (P) for the cells treated with+/  3-ABA.
Global increase in levels of DNA methylation in
cultured cells upon exposure to 3-aminobenzamide
(3-ABA), an inhibitor of poly(ADP-ribose) polymerases
(PARP) (43), has been well documented (44). Although
details of the molecular mechanisms involved are not com-
pletely understood, PARP inhibition appears to result in
the induction of DNMT1, the major maintenance DNA
methyltransferase (45). Under our experimental condi-
tions, such treatment resulted in an 11% and a
16% (Figure 1C) increase in DNA methylation in Hela
and 3T3 cells respectively, compared to the corresponding
DNA from non-treated cultures. As shown in
Figure 1A–B, the S1, SE and P fractions of the treated
(ABA) and the corresponding untreated (N) cells exhibit
an almost indistinguishable MeCP2 distribution and
partitioning.
Treatment of the same cell lines with the DNA methy-
lation inhibitor, 5-aza-20-deoxycytidine, resulted in a 10%
decrease in the level of genomic DNA methylation in
HeLa S3 and 65±2% decrease in 3T3 (Figure 1C).
Nucleic Acids Research,2012, Vol.40, No. 7 2887However, as shown in Figure 1A–B, this did not result in a
rearrangement of MeCP2 within chromatin in either one
of them. Rather, both the level and distribution of MeCP2
were similar to the untreated and treated cells. Although
the partitioning amounts of MeCP2 across the SI/SE/P
fractions varied between 3T3 (Figure 1B-Aza) and HeLa
cells (Figure 1A-Aza) (simply reﬂecting different extent of
nuclease digestion, see above and next section) the relative
amounts of MeCP2 and its distribution were again un-
affected by the treatment.
To ensure that none of these treatments affected the
amount of MECP2 transcription, real-time RT–PCR
was performed (results not shown).
MeCP2 is enriched in the highly nuclease-accessible S1
chromatin fraction of different tissues and cell lines in a
way that depends on the extent of nuclease digestion
The next question we wanted to address was whether
enrichment of MeCP2 in the S1 fraction is a universal
feature of any living cell. In other words, do the cells of
different mammalian tissues exhibit a similar distribution
of MeCP2 amongst fractionated chromatin that is similar
to the one observed in HeLa cells?
To address this question, the chromatin from rat whole
brain, and a somatic (liver) and germline (testis) control,
were fractionated into the S1, SE and P components fol-
lowing micrococcal nuclease digestion as described above,
and the histones and associated DNA of each were
analyzed by native- and AUT-PAGE [Supplementary
Figure S2 (1) and (2)]. Despite the histone variability
(Supplementary Figure S2A-2), and different pattern of
nuclease digestion (Supplementary Figure S2A-1), the ma-
jority of MeCP2 in all instances was mainly present in the
S1 fraction (Supplementary Figure S2-MeCP2). This is in
contrast with histone H2A.X, and histone H3K27me3 and
H3K9me2, which exhibit a more tissue-dependent distri-
bution (Supplementary Figure S2A-3).
Quite strikingly, and as previously reported, MeCP2 is
present in exceedingly large amounts in brain (46,47),
when compared to the other tissues investigated
(Supplementary Figure S2B-MeCP2). We used a combin-
ation of western and electrophoretic approaches (see
Supplementary Figure S2C) to quantify the approximate
relative amount of MeCP2 in these different tissues, and to
estimate the number of MeCP2 molecules per mole of
nucleosome in the brain, using histone H4 as a reference.
The amount of protein expressed in this tissue
(Supplementary Figure S2D-1), determined in this way,
is  20- to 30-fold greater than that of any other tissue,
and is present at nearly one molecule per every three nu-
cleosomes, in whole brain tissue. Also, the brain had a
relative fold difference of 19.5±0.5 (SD) times more
MECP2 mRNA than the mixed cDNA comparator. The
liver had an MECP2 relative fold difference of 0.33±0.1
(SD), while testis showed a difference of 0.85±0.02 (SD).
By this analysis, the brain had more than 22 times the
amount of MECP2 mRNA compared to testis, and
more than 59 times the amount when compared to the
liver.
To determine the inﬂuence of MNase digestion time in
the distribution of MeCP2 amongst brain chromatin, a
time-course digestion of isolated nuclei was carried out
(Figure 2A) for 2, 4, 8 and 12min, as described in the
ﬁgure legend, and fractionated into S1, SE and P. At
low MNase concentration (low extent of digestion),
the data reveal an interesting redistribution of MeCP2
A
BC
Figure 1. Distribution of MeCP2in HeLa cells in response to treatment with DNA methylating and de-methylating agents. (A) Western (MeCP2)
blot analysis of the S1, SE and P chromatin fractions obtained from the nuclei of HeLa S3 cultures grown in the absence N (native) or in the
presence of: 2mM 3-ABA, methylated (ABA); 1mM 5-aza-20-deoxycytidine, de-methylated (Aza). Coomassie blue-stained or antibody detected
histone H4 (H4) was used for normalization purposes. (B) Western blot analysis of the S1, SE and P chromatin fractions obtained from the
nuclei of mouse 3T3 ﬁbroblast cultures grown in the absence N (native) or in the presence of: 2mM 3-ABA, methylated (ABA); 1mM
5-aza-20-deoxycytidine, de-methylated (Aza). The upper part corresponds to the MeCP2 western and the lower part is a Comassie blue stained of
the SDS–PAGE after electroblotting. CM: Chicken erythrocyte histone marker. (C) HPLC-determined relative meC/C percentile of the mouse 3T3
ﬁbroblasts used for the analysis shown in (B).
2888 Nucleic Acids Research, 2012,Vol.40, No. 7from fraction P into the mononucleosome containing S1
fraction, as a function of digestion time. Interestingly, the
amount of MeCP2 present in the histone H1-containing
(Supplementary Figure S2-2), soluble polynucleosome
fraction (SE) is relatively low when compared to the
other two fractions, at any given digestion time. This
suggests that a signiﬁcant fraction of MeCP2 is loosely
bound in the P fraction, and it is readily freed of its
DNA interaction upon nuclease digestion. Eventually,
most of the MeCP2 bound in the P fraction can be
released into S1 (Figure 2B). It is important to note that
the majority of nuclear MeCP2 is DNA bound, as very
little (2.4%) MeCP2 is released into S1 in the absence of
MNase digestion (Figure 2C).
When levels of DNA methylation in S1, SE and P
fractions obtained under the digestion conditions used in
Figure 2B were determined, we found that it was higher in
both S1 and P, in comparison to the SE fraction (20% and
4.6% higher than SE, respectively) (Figure 2D). The level
of S1 methylation was about 18% higher than that of
chromatin in the nuclei before MNase digestion.
Analysis of the levels of DNA methylation in the
fraction P of Figure 2A exhibited a decrease in the trend
of DNA methylation upon increased digestion time
(results not shown).
The higher level of DNA methylation associated with
the S1 fraction (20%) suggests that a signiﬁcant part of the
protein is bound to methylated DNA regions of the
genome.
A fraction of weakly chromatin-bound MeCP2 is not
associated with nucleosomes in brain
To gain further insight into the differential distribution of
MeCP2 amongst chromatin, S1 and SE fractions from the
brain of several mammalian species (Figure 3A) were
prepared and subjected to sucrose gradient fractionation
[Figure 3C(1) and (2)]. As shown by western blot analysis,
>50% of MeCP2 in both the S1 and SE fractions partition
within the upper part of the gradient, in the region corres-
ponding to free MeCP2.
When using these fractionation procedures, the distri-
bution of brain MeCP2 is quite different from that
exhibited by MeCP2 in liver (Figure 3D), or HeLa cells
(results not shown). In these two later instances, and in
high contrast to what was observed in brain, the majority
of MeCP2 in both S1 and SE fractions is found associated
with nucleosomes. Importantly, nuclei of whole brain
were found to possess  30% higher levels of DNA methy-
lation than those of liver (Figure 3B)
The presence of non-nucleosome associated MeCP2 in
the sucrose gradient fractionation of brain chromatin
suggests the existence of two MeCP2 populations with dis-
tinct chromatin-binding proﬁles, in this tissue. To further
conﬁrm this, we performed a salt extraction of rat brain
Figure 2. Preferential fractionation of MeCP2 with the S1 fractionation depends on the extent of micrococcal nuclease digestion. (A) Time-course
digestion of rat whole-brain nuclei with MNase at 10U/mg of DNA for 2, 4, 8 and 12min followed by fractionation to yield S1, SE and P. The
upper panel shows a western blot for MeCP2 that is normalized for H4. Lower panel contains 4% native acrylamide gel of the DNA associated with
the S1, SE and P. CE: chicken erythrocyte histones; M: pBR322—CfoI-digested marker. (B) Same as in (A), but using MNase at 30U/mg of DNA
for 15min. The roman numerals (I–IV) in both (A) and (B) indicate the DNA fragments corresponding to mono-, di-, tri- and tetra-nucleosomes
respectively. (C) Western blot analysis of MeCP2 released from brain nuclei without (–) and with (+) micrococcal nuclease digestion treatment reveals
that essentially all nuclear MeCP2 is bound to chromatin. (D) HPLC-determined relative meC/C percentile of the fractions shown in (B).
Nucleic Acids Research,2012, Vol.40, No. 7 2889and liver nuclei (Figure 3E) in order to separate
sub-populations of MeCP2 exhibiting differential
binding, as well as histone H1, in both tissues. Similar to
what had been described earlier (41), brain MeCP2
exhibits a bimodal elution that takes place at salt concen-
trations lower than those required for MeCP2 extraction
in liver. For instance, at 0.35M NaCl,  80% of MeCP2
has come free in brain, whereas only 15% has been
released in liver. This is in contrast to the behavior of
H1, which, in both tissues, exhibits very similar elution
trends that begin at salt-concentrations greater than
those required to extract MeCP2.
MeCP2 is broadly distributed throughout non-condensed
chromatin regions in neuronal nuclei and is also
associated to the peripheral regions of
heterocromatic domains
Microscopy techniques were used to investigate the distri-
bution of MeCP2 in neuronal nuclei. Fluorescence
microscopy carried out on brain sections stained with an
MeCP2 antibody (Figure 4) show that, in contrast to the
predominant heterochromatin localization observed in
non-neuronal cell lines (5,48), in rat neurons, MeCP2 is
broadly distributed throughout both hetero- and euchro-
matic domains (Figure 4). Only a relatively small fraction
of MeCP2 was observed to colocalize with H3K27me3,a
well-established heterochromatin marker (Figure 4, green
ﬂuorescence).
To analyze this result in further detail, we examined
the distribution of MeCP2 in neuronal nuclei with
immunogold particle localization using TEM.
Representative samples of the many images collected
using this protocol, are shown in Figure 5. In all the
images analyzed, the gold particles were distributed
mainly in the regions of the nuclei containing low-density
(unfolded) euchromatin, or at the periphery of the highly
condensed heterochromatin domains. Very few particles
were observed within the tightly packed regions of chro-
matin, and still fewer in the cytoplasm (not shown).
Figure 3. A fraction of MeCP2 in the brain is weakly associated with chromatin and is not associated with nucleosomes. (A) Western blot analysis of
the MeCP2 partitioning in the S1, SE and P chromatin fractions from the brain of different mammalian species. (B) HPLC-determined relative meC/
C percentile in the nuclei isolated from rat brain and liver. (C) Sucrose gradient fractionation of the S1 (1) and SE (2) chromatin fractions from the
brain. The upper part depicts the absorbance (260nm) proﬁle of the fractions collected along the gradient (dark line). The lighter line shows the
proﬁle (absorbance at 230nm) of recombinant MeCP2 run under the same conditions. The lower panel shows the western blot analysis of fractions
collected along the gradient using MeCP2 and H4 antibodies. (D) Sucrose gradient fractionation of the S1 and SE chromatin fractions from rat liver.
The lower part shows a Coomassie blue-stained SDS–PAGE used for the analysis of the fractions (H) and the corresponding western blot analysis
using an MeCP2 antibody (W). (E) Salt extraction of MeCP2 and histone H1 from rat brain and liver.
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histone H2A.X and speciﬁc histone H3 PTMs
In order to identify epigenetic factors that may inﬂuence
MeCP2 localization to speciﬁc nucleosomes in different
chromatin environments, different nucleosome compo-
nents were investigated (Figure 6). These included
histone variants or histone post-translational modiﬁca-
tions that may serve as epigenetic signals to facilitate
and distinguish MeCP2 binding between heterochromatin
and euchromatin. Native coimmunoprecipitations were
performed using mononucleosomes obtained from S1
and SE chromatin fractions and an MeCP2 antibody,
followed by probing for the respective histone variant or
PTM.
MeCP2wasobservedtointeractwithH2A.X-containing
mononucleosomes in both the S1 and SE fractions. This
interaction was more enriched in the S1 than in the SE
when the precipitated amounts were compared to their re-
spective inputs. (Figure 6A–B). No associations, however,
were observed with g H2A.X, H2A.Z, or acetylated H2A.Z
in either S1 or SE (Figure 6A–B). We used coimmunopre-
cipitated mononucleosomes probed for H4 and MeCP2 by
western blotting as a control.
Interactions of MeCP2 with mononucleosomes contain-
ing speciﬁc H3 PTMs were investigated as well. In the SE,
MeCP2 associated with mononucleosomes containing the
repressive marks H3K9me2 and in a separate pull-down,
H3K27me3. No interactions were observed with H3K4me3
(Figure 6D), a PTM associated with transcriptionally
active regions. Similar interactions were also observed in
the S1 of MeCP2 pull-downs of mononucleosomes;
however, no interactions were observed with H3K9me2
(Figure 6C). Of note, H3K27me3 in the S1 was greatly
enriched in the MeCP2-immunoprecipitated nucleosomes
compared to the input (Figure 6C).
MeCP2’s ability to distinguish nucleosomes containing
different H3 PTMs in brain is very interesting. It raises
the question as to whether MeCP2 can directly interact
with the N-terminal ‘tail’ of H3, or whether this inter-
action additionally depends on the presence of
nucleosomally organized methylated DNA. A recent
survey using a SILAC-based proteomics approach (49)
has identiﬁed a plethora of nucleosome-interacting
proteins, including MeCP2. Based on these results, it
appears that both DNA and histone methylation are
required for the binding of MeCP2. Among the histone
H3 PTMs involved with MeCP2 binding within this
setting, a strong enrichment for H3K4me3, and a
moderate enrichment for H3K9me3 and H3K27me3,
was observed. In all these three instances, binding of
MeCP2 additionally required the presence of DNA
Figure 4. MeCP2 is broadly distributed throughout the interphase nucleus of neurons and exhibits a reduced colocalization with H3K27me3. The
image shows a thin section of rat brain stained with antibodies recognizing trimethylated lysine 27 of histone H3 and MeCP2. Total DNA was
stained with DAPI. A z-series was collected and the image series was processed by deconvolution. A maximum intensity projection image was then
generated for each channel. The bottom right panel shows a composite image of the trimethylated lysine 27 of histone H3 (green) and MeCP2 (red).
Regions enriched in both appear as yellow in the composite image. The trimethylated lysine 27 was found to be enriched in the most dense regions of
chromatin. MeCP2 was broadly distributed throughout the interphase nucleus, showing association with both heterochromatin and euchromatin.
Examples where trimethylated lysine 27 and MeCP2 are both enriched are highlighted with arrows.
Nucleic Acids Research,2012, Vol.40, No. 7 2891Figure 6. MeCP2 is associated with mononucleosomes containing histone H2A.X and histone H3 PTMs. (A–D) Mononucleosomes from S1 and SE
fractions were coimmunoprecipitated under native conditions using a MeCP2 antibody. The immunoprecipitated nucleosomes were then analyzed by
western blot using the antibodies indicated. Normal rabbit IgG was used as a non-speciﬁc control. The pull-downs for both the MeCP2 antibody and
IgG were compared to a normalized initial sample input used in the coimmunoprecipitations. (E) MeCP2 pull-down experiments using H3
N-terminal peptides with several PTMs. (1) MeCP2 western blot analysis after pull-down using biotinylated peptides and streptavidin beads. (2)
Quantiﬁcation of the results in (1). Results are expressed as percent of MeCP2 eluted compared to total input. Error bars represent standard error of
the mean of triplicate experiments.
Figure 5. A fraction of MeCP2 localizes at the periphery of highly dense chromatin structures. (A and B) Two transmission electron microscopy
magniﬁcation views of neuron nuclei showing the immunogold (black dots) localization of MeCP2.
2892 Nucleic Acids Research, 2012,Vol.40, No. 7methylation, and no binding could be detected in its
absence. To analyze this relationship further, we per-
formed pull-down experiments using streptavidin-
immobilized biotinylated peptides corresponding to the
N-terminal tail of H3, each containing a unique, or set
of PTMs (Figure 6E). While this data conﬁrms the
ability of MeCP2 to interact to different extents with
histone PTMs, the lack of binding to H3K27me3
strongly suggests that recognition of this signal is
strongly dependant on nucleosomally arranged
methylated DNA. The ability of MeCP2 to interact
with both active (H3K4me3, H3K9/14Ac) and repressive
(H3K9me2–3, H3K27me3) PTM markers supports the
notion of this protein being a transcriptional regulator
(18), rather than a mere transcriptional repressor as it
was initially thought (50).
MeCP2 interacts with the N-terminal region of H2A and
its in vitro nucleosome binding afﬁnity is decreased in the
presence of H2A.X
In an initial attempt to characterize the molecular involve-
ment of histones in the interaction of MeCP2 with
the brain S1 fraction nucleosomes, we performed some
preliminary cross-linking analysis. We took advantage of
a powerful method that uses isotopically (deuterium)
labeled amine-reactive crosslinkers which can be cleaved
chemically (i.e. D12-EGS) (51), by light (i.e. BiPS)
(52), or by collision-induced dissociation (i.e. CBDPS)
(53) that was recently developed at the Genome
BC Proteomics Centre at UVic. The data thus obtained
(Supplementary Figure S3) indicated that a region on the
C-terminal transcription repression domain of
MeCP2 (KAEADPQAIPK, residues 266–275) is in very
close proximity to, and likely interacts with, a region
(AKSR, residues 16–19) located at the N-terminal end
of H2A.
Also, and because of the association observed between
H2A.X and MeCP2 in the previous section, we repeated
some of our previous in vitro MeCP2-nucleosome inter-
action studies (8), but using histone H2A.X-containing
nucleosomes. The pattern of MeCP2 binding to
H2A.X-containing nucleosomes (Supplementary
Figure S4) is very similar to that observed with linker
histones (38). Accordingly, the presence of H2A.X/
gH2A.X decreases the ability of histone H1 to bind to
the nucleosome (38). Given the similarity with which
MeCP2 and linker histones bind to the nucleosome
(8,54,55), this is somewhat not surprising.
DISCUSSION
DNA methylation is not the only determinant of MeCP2
binding to chromatin
The observed differential distribution of MeCP2
(Supplementary Figure S2B) may be linked to distinct
regulatory roles for MeCP2 in different tissues. A
previous study assessed this tissue variability, but using
different approaches to normalization (47). However, in
contrast to our results, no correlation between the protein
and mRNA expression was found (47).
MeCP2 was ﬁrst identiﬁed based on its ability to recog-
nize and bind methylated DNA (41,56), and was proposed
to work as a global repressor. In an attempt to discern
between this scenario and that of MeCP2 acting as a tran-
scriptional regulator that binds to highly speciﬁc
methylated regions of the genome we treated HeLa and
mouse ﬁbroblast 3T3 cell lines with chemicals that global-
ly change the levels of DNA methylation (Figure 1). The
results obtained in this way, show that not only is the chro-
matin distribution of MeCP2 unaffected by the non-
physiological treatments designed to alter the DNA
methylation, but they do not seem to have any major
impact on the levels of MeCP2 present in the treated
cells (compare Figure 1A–B N with Aza and ABA).
These results are in agreement with the FRAP experiments
performed in the presence of Aza-deoxycytidine
(48) which showed that the mobility of MeCP2 in the
nucleus was not dependent on the extent of global methy-
lation of DNA. The comparable amounts of MeCP2
observed in 3T3 cells where the levels of DNA methylation
have decreased by 65% (Figure 1C) together with the
chromatin distribution similarity would support the
notion that part of MeCP2 is bound to non-(DNA)
methylated regions of the genome (42,57). Alternatively,
in these cell types MeCP2 may also bind to nucleosomes
containing methylated histones (Figure 6)
However, the above results need to be taken cautiously
as they have been carried out in mammalian cell lines
where, as in the case of liver (Figure 3D) most of
MeCP2 is bound to nucleosomes (results not shown). It
is possible that a completely different situation occurs in
brain where a large increase in MeCP2 is observed
(Supplementary Figure S2D). Not only this, the higher
levels of DNA methylation present in this tissue when
compared to liver (Figure 3B) or to the above cell lines
(Figure 1C) could lead to a different situation where
binding to methylated DNA is more prevalent. Indeed,
the difference in DNA methylation between brain and
liver (Figure 3B) is signiﬁcant and may account for the
greater abundance of MeCP2 observed in this tissue.
Statistically, a 1% increase in methylated cytosine can
easily provide a binding site every three nucleosome
equivalent regions in the brain.
MeCP2 and the organization of brain chromatin
The large amount of MeCP2 in adult brain (Supplementary
Figure S2B–D) (47), especially in neurons (46) and our
reported MeCP2 chromatin partitioning have implications
for MeCP2-mediated changes in chromatin organization.
It has been estimated that, in cortical neurons, there is
approximately one molecule of MeCP2 per every two nu-
cleosomes (46), a value similar to that observed by us of
one molecule per every three nucleosomes in whole
unfractionated brain. Also, there is plenty of evidence
that the chromatin soluble fraction of cortical neurons
upon MNase digestion exhibits a repeat length of
 160bp, which is lower than that of 190–200bp
observed in glial cells and other somatic tissues (58,59).
Although not the purpose of our current analysis, as
no attempt was made to purify cortical neuron nuclei,
Nucleic Acids Research,2012, Vol.40, No. 7 2893we consistently observed a shorter DNA repeat with our
brain chromatin samples. The median value was centered
at  170bp for the SE fraction chromatin containing a full
amount of histone H1, when compared to the values
obtained from other tissues, or to the P fraction
(Supplementary Figure S2A and Figure 2B).
Interestingly, the decrease in nucleosome repeat length
observed in mature neurons (59) takes place in a gradual
fashion as the brain matures and levels of MeCP2
increase. In quiescent neurons, DNMT3A-mediated
changes in DNA methylation during development would
presumably be favored at linker regions (60). Taken
together, it is tempting to speculate that in such cells,
providing the average number of nucleosomes remains
relatively constant during maturation (61), a decrease in
repeat length would come at expense of exposing longer
regions of linker DNA, which may then become bound by
MeCP2 (Figure 7). These regions would correspond to the
non-nucleosomally associated MeCP2 in fractions S1 and
SE (Figure 3B–C). Furthermore, in a situation where one
molecule of MeCP2 is present every two nucleosomes, one
would predict a more homogeneous distribution through-
out the S1, SE and P fractions in these cells. While this is
speculative, and requires further attention, one could
envisage these regions comprising some of the
MeCP2-mediated chromatin looping structures (16) and/
or the regions associated with the nuclear matrix (62). The
latter could explain the transition observed from the P to
S1 fraction observed in Figure 2A.
MeCP2 interacts with nucleosomes containing speciﬁc
histone variants and post-translational modiﬁcations
DNA methylation within a sequence speciﬁc context has
been shown to direct MeCP2 binding (5). However, it is
hard to envisage how such a simple mechanism is sufﬁ-
cient to account for the multiple potential roles in regula-
tion of gene expression by MeCP2. Hence, we decided to
check for the presence of other nucleosomal components
that could allow MeCP2 to distinguish between various
binding targets (63). As the H2A C-terminal tail and the
H3 N-terminal tails exit the nucleosome (64) close to the
site where MeCP2 has been proposed to bind (8,9), can-
didate variants and PTMs of these two core histones were
investigated using coimmunoprecipitations of brain chro-
matin (Figure 6).
A novel and strong association was observed between
MeCP2 and H2A.X-containing mononucleosomes in S1
chromatin (Figure 6A). The association of MeCP2 with
H2A.X-containing nucleosomes is interesting. H2A.X has
been shown to accumulate during neuron development
(65,66) and to affect neuron stem cell proliferation and
neuron output (67). MeCP2 interacts with the Brahma
subunit of the SWI/SNF remodeling complex (68) and
both MeCP2 and SWI/SNF have been shown to cyclically
associate with an inducible promoter undergoing tran-
scriptional activation (69). The binding of MeCP2 to
H2A.X nucleosomes may be functionally linked through
SWI/SNF, rather than to a direct binding preference for
nucleosomes containing this variant. Indeed, the results
shown in Supplementary Figure S4 indicate that it is
highly likely that the association between MeCP2 and
H2A.X-containing nucleosomes is of a casual nature.
H3K9me2 had a broad chromatin distribution within
whole brain (Supplementary Figure S2A-3), although it
was not observed in the cortex S1 immunoprecipitated
fraction (Figure 6C), suggesting differential specialization
of various brain regions may be regulated by a speciﬁc
combination of MeCP2, DNA methylation and histone
Figure 7. Schematic representation to illustrate the dual association of MeCP2 with different chromatin domains in the brain. Shown in the right is a
magniﬁed image of the interaction of MeCP2 within the nucleosome fraction. Methylation of DNA in the vicinity of the nucleosome (in the
proximity of the entry and exit sites of the DNA) as well as histone PTMs (such as H3K27me3) or histone variants may play a role in the
interaction. Also shown is a site of interaction of the C-terminal tail of MeCP2 with the N-terminal of histone H2A.
2894 Nucleic Acids Research, 2012,Vol.40, No. 7post-translational modiﬁcations. MeCP2 interacted with
mononucleosomes containing this PTM in the SE
fraction, but not in the S1 fraction (Figure 6C). The asso-
ciation of MeCP2 with H3K9 methylation has been
described in the IL-6 gene region (70). A direct correlation
between the binding of MeCP2 and the presence of
H3K9me2 in promoter 1 of the BDNF gene and the
I Ba gene has been reported as well (71,72). These
coimmunoprecipitation results show, for the ﬁrst time,
that MeCP2 not only directly interacts with nucleosomes
containing H3K9me2, but that this interaction is depend-
ent upon the chromatin organization in the cortex. Di-
and tri-methylated H3K9 have been shown to be marks
for DNA methylation in Arabidopsis (73) and in
Neurospora (74).
The presence of divalent PTMs, H3K27me3 and
H3K4me3, on the same histone tail has been reported to
poise the associated gene regions for either transcriptional
activation or silencing (75–77). Interestingly, MeCP2 has
been found to associate with methylated nucleosomes con-
taining H3K4me3 (49) (Figure 6E). If activation is trig-
gered, then the H3K27me3 mark is lost while the
H3K4me3 PTM is perpetuated. The opposite scenario
proceeds in the case of a repressive signal. H3K27me3,a
mark of facultative heterochromatin, was present in
MeCP2-bound nucleosomes in both S1 and SE
(Figure 6C–D). Despite its low presence in S1, a strong
enrichment for this signal was observed in the S1
pull-downs of the sheep cortex (Figure 6C). This
suggests that a major portion of MeCP2-bound nucleo-
somes contain H3K27me3 in this particular brain fraction.
Whilst the importance of the association of MeCP2 with
nucleosomes consisting of H2A.X, methylated H3K9 and/
or H3K27 remains to be determined, our results indicate
that in the in vivo setting, DNA methylation is not the sole
determinant of MeCP2 binding to chromatin, and that the
molecular constraints involved in the binding of MeCP2
to chromatin are more complex than originally envisaged.
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